Efficacy of Neoadjuvant Immunochemotherapy in Pulmonary Lymphoepithelioma Carcinoma Compared With Lung Squamous Cell Carcinoma and Adenocarcinoma: A Retrospective Cohort Study
Immune-boosting chemotherapy shows promise for a rare young-adult lung cancer, achieving outcomes comparable to more common types.
This multicenter retrospective study demonstrates that neoadjuvant immunochemotherapy achieves promising pathological response rates (pCR 20%, MPR 45%) and 2-year EFS of 76.6% in pulmonary lymphoepithelioma-like carcinoma, a rare EBV-associated lung cancer primarily affecting younger Asian patients. IPTW-adjusted outcomes were comparable to more common lung cancer subtypes, supporting this approach as a reasonable option for this underserved rare cancer.
What the study was
- Study design
- Retrospective multicenter cohort with IPTW-adjusted comparative analysis
- Population
- PLEC patients (n=40, mean age 50.2y, 57.5% female) plus matched LUSC (n=83) and LUAD (n=82) comparators receiving neoadjuvant immunochemotherapy, 2 centers China
- Sample size
- 205
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Medicine
Why it surfaced
Rare EBV-associated lung cancer with limited prospective data. This represents one of the larger comparative cohorts for PLEC neoadjuvant therapy. Notable for young patient population (mean 50y) with high-PD-L1 expression.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.